Aurora Cannabis Stock Falls as Canadian Producer Expects International Sales to Decline

Aurora Cannabis (ACB) shares fell sharply after the company announced expectations of declining international cannabis sales, offsetting gains from increased Canadian medical cannabis revenue. The company's U.S.-traded stock dropped over 17%, despite being up approximately 14% year-to-date. While quarterly revenue reached C$90.5 million, driven by a nearly 50% increase in medical cannabis sales to C$67.8 million, the anticipated international sales decline is projected to impact overall global cannabis revenue in the current quarter.

Analysis

Aurora Cannabis (ACB) shares experienced a substantial decline, falling over 17% in U.S. trading, subsequent to its fiscal fourth-quarter earnings release and revised guidance. This significant intraday drop occurred even as the stock, including these recent losses, maintained a year-to-date gain of approximately 14% for 2025. The primary catalyst for the negative market sentiment, reflected by a sentiment score of -0.5 (moderately negative), is the company's projection of "temporary declines" in its international sales. Management anticipates this downturn will offset the continued expansion within its Canadian medical cannabis operations, which saw sales rise nearly 50% year-over-year to C$67.8 million in the fourth quarter. For this period, Aurora reported total revenue of C$90.5 million and a narrowed net loss of C$17.2 million, compared to C$20.3 million in the prior-year quarter. However, the forward-looking guidance indicates an expected decrease in global cannabis revenue for the current quarter compared to fourth-quarter levels, directly attributable to the anticipated weakness in international markets.

Key Decisions for Investors

• Investors should closely monitor developments in Aurora's international markets, as the projected "temporary declines" pose a significant headwind to overall revenue growth despite strong Canadian medical sales.
• Given the sharp stock price reaction against a backdrop of year-to-date gains, a reassessment of risk exposure to ACB may be warranted, particularly considering the contrasting performance between its domestic strength and international weakness.
• The company's ability to navigate the international sales downturn, reverse this trend, and maintain its progress in narrowing net losses will be key indicators to watch in subsequent quarters.